PSS14 COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2011 |
| Reihe/Periodikum: | Value in Health ; volume 14, issue 3, page A55 ; ISSN 1098-3015 |
| Verlag/Hrsg.: |
Elsevier BV
|
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-28560828 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1016/j.jval.2011.02.316 |
